Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - la esclerosis múltiple remitente-recurrente - inmunosupresores - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - la esclerosis múltiple remitente-recurrente - los inmunosupresores selectivos de inmunosupresores - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

teva gmbh - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma s.l. - fumarato de dimetilo - cÁpsula dura gastrorresistente - 120 mg - fumarato de dimetilo 120 mg - dimetil fumarato

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma s.l. - fumarato de dimetilo - cÁpsula dura gastrorresistente - 240 mg - fumarato de dimetilo 240 mg - dimetil fumarato

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - fumarato de dimetilo - cÁpsula dura gastrorresistente - 120 mg - fumarato de dimetilo 120 mg - dimetil fumarato

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - fumarato de dimetilo - cÁpsula dura gastrorresistente - 240 mg - fumarato de dimetilo 240 mg - dimetil fumarato

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - fumarato de dimetilo - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - teriflunomida - comprimido recubierto con pelÍcula - 14 mg - teriflunomida 14 mg - teriflunomida

Unión Europea - español - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.